Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Clinical ASCVD would indeed be under secondary prevention

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Mellowmood77 Member Profile
 
Followed By 26
Posts 533
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences GlobeNewswire Inc. - 6/21/2019 1:39:19 PM
Mellowmood77   Tuesday, 09/17/19 12:29:06 PM
Re: Whalatane post# 214783
Post # of 220248 
Clinical ASCVD would indeed be under secondary prevention and an event is not required:

Documented coronary artery disease (CAD; one or more of the following primary criteria must be satisfied):
• Documented multi vessel CAD (≥50% stenosis in at least two major epicardial
coronary arteries – with or without antecedent revascularization);

• Documented prior MI;

• Hospitalization for high-risk non-ST-segment elevation acute coronary syndrome
(NSTE-ACS) (with objective evidence of ischemia: ST-segment deviation or
biomarker positivity).


2. Documented cerebrovascular or carotid disease (one of the following primary criteria must be satisfied):

• Documented prior ischemic stroke;

• Symptomatic carotid artery disease with ≥50% carotid arterial stenosis;

• Asymptomatic carotid artery disease with ≥70% carotid arterial stenosis per
angiography or duplex ultrasound;

• History of carotid revascularization (catheter-based or surgical).


3. Documented peripheral arterial disease (PAD; one or more of the following primary criteria must be satisfied):

• Ankle-brachial index (ABI) <0.9 with symptoms of intermittent claudication;

• History of aorto-iliac or peripheral arterial intervention (catheter-based or
surgical).


Primary prevention requires you to have diabetes type 1 or type 2 plus one additional risk factor in the reduce-it trial.

If you have diabetes and your additional risk factor is, say, ankle-brachial index (ABI) <0.9 with symptoms of intermittent claudication, or anything from the previous table, you will be counted as secondary not primary.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist